Study for effect of Danggui Shaoyao Powder in the treatment of Non-alcoholic Fatty Liver Disease

Shuguang Hospital affiliated to Shanghai University of TCM0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Meet the diagnostic standard of the nonalcoholic fatty liver disease;
•2. Aged 18-65 years old;
•3. MRI-PDFF is greater than or equal to 10%;
•4. ALT is greater than the upper limit of normal, and less than or equal to 5 times the upper limit of normal;
•5. Signed informed consent.

•1. Those who have used other liver-protecting and enzyme-lowering drugs which might affect the efficacy evaluation in the past 3 months;
•2. Patients with alcoholic fatty liver (male alcohol intake> 20g / d, female alcohol intake> 10g / d);Patients with cirrhosis, HBV, HCV and other liver diseases; Patients with autoimmune liver disease; People who are taking any drug which might cause fatty liver;
•3. Those with normal liver function;
•4. Those who have undergone gastrointestinal weight loss surgery in the past year or those who have lost weight by more than 10% after taking weight-loss drugs within the past 3 months;
•5. Pregnant women, lactating women, patients with primary diseases such as cardiovascular, lung, kidney, hematopoietic system, and other major diseases such as malignant tumors.

发起方

Shuguang Hospital affiliated to Shanghai University of TCM